Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001330301 | SCV001521942 | uncertain significance | Intellectual disability, autosomal dominant 5 | 2019-12-10 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001330301 | SCV001620160 | likely benign | Intellectual disability, autosomal dominant 5 | 2024-06-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003169546 | SCV003906025 | uncertain significance | Inborn genetic diseases | 2023-02-27 | criteria provided, single submitter | clinical testing | The c.1724G>A (p.R575H) alteration is located in exon 11 (coding exon 11) of the SYNGAP1 gene. This alteration results from a G to A substitution at nucleotide position 1724, causing the arginine (R) at amino acid position 575 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004740668 | SCV005354510 | uncertain significance | SYNGAP1-related disorder | 2024-06-03 | no assertion criteria provided | clinical testing | The SYNGAP1 c.1724G>A variant is predicted to result in the amino acid substitution p.Arg575His. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0042% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |